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Received 5 November 2006; received in revised form 15 January 2007; accepted 22 January 2007; Available online 22 February 2007AbstractObjective: To test the effects of a continuous medium flow inside DegraPolW scaffolds on the reepithelialization and revascularization
processes of a tissue-engineered trachea prosthesis.Methods: In this proof-of-principle study a continuous medium flowwas maintained within a
tubular DegraPolW scaffold by an inserted porous catheter connected to a pump system. The impact of the intra-scaffold medium flow on the
survival of a tracheal epithelial sheet wrapped around and on chondrocyte delivery to the DegraPolW scaffold was studied. In the chick embryo,
chorioallantoic membrane (CAM) model angiogenesis within the biomaterial was investigated. Results: Scanning electronic microscopy (SEM)
images showed an intact epithelial layer after a 2-week support by continuous medium flow underneath. On histology, three-dimensional cell
growth was detected in the continuous delivery group. The CAM assay showed that angiogenesis was enhanced within the DegraPolW scaffolds
when vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was added to the perfusate. Conclusions: Taken together,
these results demonstrated that the built-in perfusion system within DegraPolW scaffolds was able to maintain an intact tracheal epithelial layer,
allowed a continuous delivery of cells, and kept an efficient VEGF/VPF expression level which accelerated angiogenic response in the CAM assay.
This design combines the in vitro and in vivo parts of tissue engineering and offers the possibility to be used as an in vivo bioreactor implanted for
the tissue-engineered reconstruction of trachea and of other organs.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Tissue engineering, aimed at alleviating donor organ
shortage by providing an alternative treatment for tissue
and organ failure, has emerged as a promising new field in
medical science [1]. Led by the illusionary simplicity of
developing a tubular cartilage tissue to replace the native
trachea, many scientists focused their research on tissue-
engineered trachea assuming it to be a straightforward
procedure. Unfortunately, all animals died within 1 week
when a circumferential replacement of the trachea was
performed with a tubular cartilage tissue only. Autopsies
showed lethal airway obstructions caused by granulation
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doi:10.1016/j.ejcts.2007.01.045have highlighted the importance of the reepithelialization
process to achieve a functional trachea substitute
[3—5]. The experience gained from tissue-engineered skin
demonstrated that epithelial cells have better survival
chances on a well-vascularized wound surface [6,7], a
clear proof that revascularization is the essence of
reepithelialization.
In contrast to other parenchymal organs the trachea
is supplied by a network of small vessels that makes
direct revascularization difficult. Microanastomoses were
attempted, but that is not the way to follow [8]. Even
immediate orthotopic tracheal replacements were doomed
to fail as the capillary networks only penetrate into the
implant for no more than 2 cm (i.e., 4 cm bilaterally) across
the two anastomoses. This revascularization process nor-
mally requires several months [9]. In an implant longer than
3 cm the centrally located epithelial cells die soon after
implantation and fail to maintain an intact basement
membrane causing tracheal stenosis by granulation tissue
hyperplasia.urgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Scheme for the assembly of an in vivo bioreactor model (A); cell
delivery test model, 107 rat chondrocytes were added into the medium daily. ATo improve the survival of a continuous epithelial layer
and to accelerate the revascularization process of a tissue-
engineered trachea substitute, a perfusion system was
designed inside a tubular DegraPolW polymer [10,11],
allowing medium to flow and to permeate throughout the
scaffold. As it has been proved difficult to successfully
simulate an in vivo regenerative environment in vitro [12],
the tissue-engineered trachea with its integrated perfusion
system is suggested to be implanted into the recipient as soon
as possible. After implantation the intra-scaffold perfusion
system will be connected to an extra-corporeal pump system
which works as nutrition assist device for the avascular
tissue-engineered trachea to maintain an intact tracheal
epithelial cell layer throughout the whole regenerative
period until the slow process of revascularization has been
achieved. During this period the recipient will function as an
in vivo bioreactor for the implanted tissue-engineered
trachea. Further advantages of this in vivo bioreactor design
include the possibility of continuous or intermittent cell
seeding and the delivery of growth factors to accelerate the
revascularization process of newly implanted tissue-engi-
neered prostheses.
In this study we describe a simple proof-of-principle
model to demonstrate the feasibility of such an approach.centrifuge tube was used to protect the DegraPolW scaffold (B); CAM angiogen-
esis test model (C,D). The perfusate was changed daily and the flow rate
remained at a steady volumetric flow of 5 ml/h in all the tests. CAM: chick
embryo chorioallantoic membrane.2. Materials and methods
2.1. Description of the perfusion model
A catheter (6F angiographic catheter, 1 mm inner
diameter, Cordis Corporation, Spreitenbach, Switzerland)
was inserted into the lumen of a DegraPolW tube (Institute of
Polymer Research ETHZ, Zurich, Switzerland) of 2 cm in
length, 2 mm in inner diameter, and 6 mm outer diameter.
Half of the catheter wall located inside the DegraPolW lumen
was cut to allow the medium leak out of the catheter and
permeate into the scaffold. The ends of the catheter were
connected to two peristaltic pumps (IPC high-precision multi-
channel dispenser, ISMATEC, Zurich, Switzerland) through 60-
cm long Tygon LFL tubes (1.6 mm inner diameter, ISMATEC,
Zurich, Switzerland). One pump continuously supplied
perfusate into the scaffold while the other removing the
waste products both at a steady volumetric flow of 5 ml/h
(Fig. 1A).
2.2. Reepithelialization test
The human tracheal epithelial cell line 16HBE14o
(generously provided by Dr Jordi Ehrenfeld, Faculte´ des
Sciences de Nice, France) was cultured as published
previously [13]. In short, cells were cultured in Dubecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum (FCS), 584 mg/l L-glutamine, 50 mg/ml
gentamycin, 100 mg/ml streptomycin, and 100 U/ml peni-
cillin G, incubated at 37 8Cwith 5% CO2. Mediumwas changed
every other day. Cells were trypsinized using trypsin/EDTA
solution (0.05%/0.02%, PAN Biotech, Aidenbach, Germany)
and 1  107 cells were harvested and seeded onto each
xenogenic (porcine) acellular dermal matrix (ADM) (Qidong
Biotechnologies Ltd., Shanghai, China), 2 cm  2 cm in size,and 0.02 cm in thickness [14,15]. Stored in an incubator
overnight for cell attachment, five ADM scaffolds seeded with
epithelial cells were then wrapped around a DegraPolW tube
connected to the perfusion pump system and cultured in an
incubator for 2 weeks, at 37 8C with 5% CO2 (Fig. 1B).
Scanning electronic microscopy (SEM) was performed to
monitor the continuity of the epithelial layer on the surface
of the ADM after 2 weeks.
2.3. Cell delivery test
The same perfusion model was used for delivering
chondrocytes to DegraPolW scaffolds. Rat chondrocytes were
harvested from Lewis rat xiphoids as previously described by
our group [16]. In brief, minced cartilage particles were
digested with 0.3% collagenase II (PAN Biotech, Aidenbach,
Germany) solution in fresh Ham’s F12 medium at 37 8C for
16—18 h; the resulting suspension was centrifuged at 400  g
for 5 min and the chondrocyte pellets were resuspended in
Ham’s F12 medium with 248.54 mg/l stabilized L-glutamine,
50 mg/ml of gentamycin, and 10% fetal bovine serum (PAN
Biotech, Aidenbach, Germany) and cultured in 75-cm2 vented
polystyrene cell culture flasks (Costar 3376, Corning, Inc.,
Corning, NY, USA) in an incubator at 37 8C with 5% CO2. The
medium was changed twice a week. Cells were trypsinized by
trypsin/EDTA solution for use. Rat chondrocytes 1  107 were
harvested daily and resuspended in 250 cc Ham’s F12medium
in one 75-cm2 vented polystyrene cell culture flask which was
connected to the inlet pump through a Tygon LFL tube
(1.6 mm inner diameter, 60 cm in length, ISMATEC, Zurich,
Switzerland). This cell suspension was administered con-
tinuously into the DegraPolW scaffold while the outlet pump
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Fig. 2. SEM demonstrating an intact monolayer of epithelial cells on the
surface of xenogenic (porcine) ADM wrapped outside DegraPolW scaffold with
a continuous medium flow inside after 2 weeks. ADM: acellular dermal matrix.removed the fluid with waste products at a steady volumetric
flow of 5 ml/h. Topically seeded and static culture methods
were used as controls with 1  107 rat chondrocytes directly
seeded onto a DegraPolW tube of equal size as described
above. The samples were then placed overnight for cell
attachment and subsequently immersed in 20 cc Ham’s F12
medium in a culture dish. The cell-scaffold construction was
subsequently cultured in a CO2 incubator for 2 weeks with
1  107 rat chondrocytes reseeded daily. Each group contains
five DegraPolW tubes; 2 weeks later the 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and
histological assessments were performed to detect viable
cells within all the scaffolds.
2.4. Angiogenesis assay
Weused the ex ovo chorioallantoicmembrane (CAM)model
of chick embryos [17] to test the impact of the in vivo
bioreactor system on angiogenesis. On incubation day 12,
sixteen CAMs were randomly allocated into four groups with
four CAMs in each group. Part of the surface of the CAM
membranewaswoundedbyatinydropofalcoholatthecontact
site of the DegraPolW tube (1 cm long, 2 mm inner diameter).
Four different groups were studied: (I) static control: 1 cm
DegraPolW tube only; (II) VEGF pre-coated: DegraPolW tubes
were immersed in 5 cc F12 medium containing 4 mg/ml of
canine VEGF164 [18] (gift from PD Dr Rolf Jaussi, Paul Scherrer
Institute, Villigen, Switzerland) for 1 h before the experiment;
(III) in vivo bioreactor: a porous catheter was inserted through
the DegraPolW tube and connected to the perfusion pump
system as described above. DMEM was used as perfusate at a
steady volumetric flow of 5 ml/h (Fig. 1C,D); (IV) in vivo
bioreactor plus VEGF: same setting as that in group III, except
VEGF164 (40 ng/ml) added to the perfusion medium. After 5
days all samples were collected for histological examinations
to assess angiogenesis within the DegraPolW scaffolds.
2.5. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay
MTT assay determines viable cell numbers and is based
on the mitochondrial conversion of the tetrazolium salt 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Briefly, DegraPolW scaffolds seeded with chondrocytes were
harvested and placed in a 6-well culture plate. To each well
500 ml medium and 40 ml MTT solution were added and
incubated at 37 8C for 1 h. The supernatant was discarded and
replaced by 800 ml isopropanol with 10% formic acid. Samples
were incubated at 37 8C for an additional 5 min, vortexed for
10 min, and the MTT absorbency values of the resulting
solutionweremeasured using an ELISA reader (Dynatech 5000,
Dynatech, Billinghurst, UK) at a wavelength of 570 nm.
2.6. Histological and scanning electron microscopy (SEM)
analysis
Samples for the SEM examination were fixed in 2%
phosphate-bufferedglutaraldehydesolution, thendehydrated
with a graded isopropanol series, and air-dried. Before
analysis, the dried samples were mounted on aluminum
supports and sputter-coated with gold.DegraPolW samples from the cell delivery tests were fixed
for histological analysis with 4% phosphate-buffered for-
malin, embedded in paraffin, and sectioned using standard
histochemical technique. Slides were stained with hematox-
ylin and eosin (H&E).
One hour prior to the sample harvest, the CAMs were
injected i.v. with bisbenzimide H 33342 [19] (100 ml, 1 mg/
ml, Fluka, Buchs, Switzerland). Frozen sections of DegraPolW
samples were imaged for bisbenzimide H 33342 fluorescence
using a 360 nm excitation filter and a 450 nm long-pass
emission filter. The imaging system consisted of a fluores-
cence microscope (Leica DM RE, Leica Microsystems, Wetzlar,
Germany), a digital camera (Color-CCD Camera ‘RETIGA’,
QImaging, Burnaby, Canada), and an image software (Leica
lite, Leica Microsystem, Wetzlar, Germany).
2.7. Statistics
The MTT test data were expressed as mean  standard
deviation. We used the SPSS 8.0 software for statistical analy-
sis. Anunpaired t-testwasperformed,at a givenp-valueof less
than 0.05, which was considered as statistically significant.3. Results
3.1. Reepithelialization test
The SEM results demonstrated an intact monolayer of
tracheal epithelial cells on the surface of acellular dermal
matrix after a 2-week support by the in vivo bioreactor
device in all the samples (Fig. 2). These cells were
physiologically exposed to ambient air instead of having
been unphysiologically immersed in the medium during the
whole culture period.
3.2. Cell delivery test
The MTT test results showed no significant difference
( p > 0.05; Fig. 3) between the perfusion delivery group
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Fig. 3. MTT values at 570 nm showing no significant differences between the in
vivo bioreactor group and the conventional topically seeded and static culture
group.
Fig. 5. (A) Frozen section showing vessel formation in the ingrowth CAM tissue
of the DegraPolW scaffold in group IV (200). (B) Bisbenzimide H 33342 staining
marked the inside erythrocyte nuclei red showing normal blood vessel func-
tions.
Fig. 6. (A) In all the samples from angiogenesis test group IV erythrocytes
migrating throughout the whole DegraPolW scaffolds, even at the upper part
without any ingrowth of connective tissue, due to an increased vessel perme-
ability caused by VEGF/VPF (H&E, 200). (B) Red bisbenzimide H 33342
staining of erythrocyte nuclei proving their migration from normal functional
vessels. VEGF/VPF: vascular endothelial growth factor/vascular permeability
factor.(0.312  0.177) and the topically seeded static culture group
(0.288  0.053). The histological results demonstrated a
better three-dimensional clone formation inside the Degra-
PolW scaffolds in the perfusion group while there was only a
monolayer of chondrocytes formed on the surface of the
samples in the static culture group (Fig. 4). Chondrocytes
could be efficiently delivered to the scaffolds via the
perfusion system and the continuous medium flow improved
the extent of proliferation and even distribution of seeded
cells inside the scaffolds. It proved to be a promising
approach to combine cell seeding and cell culture systems in
tissue engineering research.
3.3. Angiogenesis assay
Histological slices from groups I and II showed almost no
sign of tissue ingrowth inside the DegraPolW scaffolds, while
samples from groups III and IV displayed more than two-third
tissue invasion. No blood vessels were found inside the
DegraPolW scaffolds in the first three groups, while
bisbenzimide H 33342 injections revealed normal functional
capillary formation inside the ingrowing tissue in group IV
(Fig. 5). Erythrocytes were detected throughout the scaffolds
due to the increased vascular permeability which was
specifically induced by the circulating VEGF, formerly called
vascular permeability factor (VPF) (Fig. 6). In one out of four
experiments in group IV we found in histology that the
ingrowing CAM tissue completely biodegraded the lower
parts of the DegraPolW tube within 5 days (Fig. 7). TheFig. 4. (A) Histological section of the in vivo bioreactor group showing a three-
dimensional chondrocyte cluster formation inside the DegraPolW scaffold. (B)
In comparison, only a monolayer of chondrocytes covered the surface of the
DegraPolW tube in the topically seeded and static culture group. (H&E staining,
100).continuous medium flow benefits the biocompatibility
characteristics of the biomaterial scaffold to facilitate tissue
ingrowth and also provide a straightforward approach for the
delivery of growth factors.4. Discussion
In this study we advanced a novel concept of in vivo
bioreactor defined as the design of a perfusion system inside
the scaffold for tissue-engineered trachea reconstruction. In
contrast to traditional bioreactor designs where the cell-Fig. 7. One histological section from the angiogenesis test group IV showing
that the CAM tissue biodegraded the lower part of the DegraPolW tube and
reepithelialized the upper part within 5 days (H&E staining, 1).
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the in vivo bioreactor contains an inter-connective pipe
system with the aim to allow the medium to flow and to
permeate throughout the entire biodegradable scaffold. In
reepithelialization experiments epithelial cells formed a
monolayer on the surface of an acellular dermal matrix with
continuous medium perfusion inside a tubular DegraPolW
scaffold underneath. The medium infiltrated through two
different biomaterials and supported the survival of epithe-
lial cells on the top surface for 2 weeks. Much larger size of
scaffolds will be needed in later clinic application, while the
structure of the novel tissue-engineered trachea prosthesis
will be similar to the one we presented in this paper. The
construct we tested can be considered as part of a large size
tubular DegraPolW scaffold embedded with several porous
feeding tubes inside and covered with tissue-engineered skin
over the inner lumen surface. These feeding tubes will be
connected to an extra-corporeal pump system to guarantee
continuous medium perfusion. The power of the outlet pump
should be adjustable to prevent medium overflow leaking out
of the tracheal prosthesis causing inappropriate space
between scaffolds and local infection. In further studies,
the maximal perfusion area by each feeding tube should be
calculated and the formation of an intact basement
membrane by these tracheal epithelial cells needs to be
addressed as it proved to be critical for preventing the
unwanted ingrowth of granulation tissues into the tracheal
lumen after implantation and for guiding normal epithelial
cells ingrowing from the two anastomoses.
The MTT assay results in the cell delivery test showed no
significant differences between the perfusion delivery and
the conventional topically seeded static culturemethod. This
result may offer advantages for future clinical applications
especially in cases of emergency patients who are not able to
wait for the time-consuming reconstruction of a tissue-
engineered trachea in vitro. In such critical clinical situations
an in vivo bioreactor could be first implanted during an
emergency operation with appropriate tissues harvested at
the same time for later isolation and expansion of cells in the
laboratory. These cells could then be seeded into the
embedded tissue-engineered trachea scaffold continuously
by daily transfusions. The histological sections in our
experiments showed three-dimensional cell growth inside
the scaffold in the perfusion delivery group while there was
only a monolayer on the scaffold surface in the control group.
This demonstrates that the dynamic perfusion within the
scaffolds efficiently improved the nutrient supply and the
metabolic waste removal. The relatively weak internal flow
shear stress seemed not to disturb the formation of cellular
interconnections within the polymeric scaffolds while
providing sufficient internal nutrient flux. The in vivo
bioreactor acted as an assist device not only to delivery
cells but also to support the metabolic needs of seeded cells
deep inside the scaffolds where no efficient diffusion from
normal surrounding tissues is available during the initial pre-
vascular period after implantation. In previous studies
Vacanti and co-workers engineered pre-formed vascular
networks on silicon and Pyrex chips with the help of themicro
fabrication technique. These microchips were sandwiched
between tissue layers to function as an artificial capillary
network [20]. In order to reduce thrombogenicity and toavoid coagulation-related problems the channel surface was
coated with endothelial cells. As an alternative for future
preclinical and clinical developments we connected the
perfusion system inside the biomaterial scaffold to an extra-
corporeal pump system separated from the circulation of the
recipient. As shown in the CAM model such an in vivo
bioreactor is thought to offer a simple and practical approach
to solve the problem associated with delayed revasculariza-
tion of tissue-engineered prostheses.
Despite the time limitation of the in vivo CAM model we
observed in the samples from group IV the presence of
erythrocytes throughout the scaffold due to the increased
vascular permeability induced by the continuous delivery of
vascular endothelial growth factor/vascular permeability
factor (VEGF/VPF) together with a much earlier neo-vessel
formation within the scaffolds as compared to the control
groups. The intravenously injected bisbenzimide H 33342
demonstrated that the newly formed CAM capillaries within
the scaffolds were functionally connected to the circulation
system of the chick embryo. These in vivo phenomena
showed that the in vivo bioreactor is able to serve as an
efficient growth factor delivery system that indeed accel-
erates the angiogenesis process. Angiogenesis requires
various growth factors that might be best applied together
or in a timed sequence [21]. In the in vivo bioreactor the
expression levels of different kinds of growth factors can be
readily controlled through the adjustment of dose concen-
trations in the perfusate. In future studies a detailed spatial
and temporal application schedule could, therefore, be
realized in long-term angiogenesis animal models in compar-
ison to other delivery approaches such as gene transfer and
growth factor-scaffold binding methods [22,23].
Recently, an in vivo bioreactor for tissue-engineered bone
was described by introducing an artificial space between the
recipient’s normal bone and the periosteum [24]. In contrast,
our design emphasizes the possible advantages of continuous
cell delivery and growth factor administration together with
the direct implantation of selected customized scaffolds into
tissue defects. To further improve the initial poor oxygena-
tion within an avascular tissue-engineered prosthesis artifi-
cial oxygen carriers such as perfluorocarbone (PFC) emulsion
[25] could be added to the perfusate to bridge the gap until
revascularization is achieved.
In conclusion, this pilot study demonstrated that con-
tinuously perfused biodegradable, tubular DegraPolW scaf-
folds supported the tracheal epithelial cell survival, allowed
growth factor and chondrocyte delivery. By the addition of
VEGF to the perfusion medium angiogenesis was enhanced in
the CAM model. The in vivo bioreactor described here
combines the formerly separated in vitro and in vivo parts in
tissue engineering research into an all-in-one concept.Acknowledgements
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